RxDoctor Payments Data

Neil Allen, MD

Neurology · Northbrook, ILNPI 1255325023

Payments from drug & device makers

$25,515in general payments, 2019–2025

Across 1,425 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • UCB, Inc.$2K
  • Supernus Pharmaceuticals, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Lundbeck LLC$999
  • Neurocrine Biosciences, Inc.$988
  • plus $15K from 54 others

What the payments were for

  • Speaking & faculty fees$5002%
  • Food & beverage$24,86397%
  • Education$1511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)157$2,756
UCB, Inc.97$2,290
Supernus Pharmaceuticals, Inc.92$1,348
Teva Pharmaceuticals USA, Inc.106$1,175
Lundbeck LLC68$999
Neurocrine Biosciences, Inc.49$988
Lilly USA, LLC44$945
Pfizer70$929
AstraZeneca(2 entities)31$760
Currax Pharmaceuticals LLC57$727
EMD Serono, Inc.46$692
Mallinckrodt Hospital Products Inc.27$682
MDD US Operations, LLC14$648
Axsome Therapeutics, Inc.28$597
Bristol Myers Squibb31$574
Avanir Pharmaceuticals, Inc.49$525
Amgen(2 entities)17$435
ANI Pharmaceuticals, Inc.16$412
Takeda Pharmaceuticals U.S.A., Inc.19$403
CSL Behring7$336
SK Life Science, Inc.18$327
Catalyst Pharmaceuticals, Inc.12$321
Upsher-smith Laboratories LLC18$316
Biogen15$302
Avadel CNS Pharmaceuticals, LLC13$301
Eisai Inc.17$286
Sanofi18$284
Johnson & Johnson15$281
Otsuka America Pharmaceutical, Inc.12$268
Harmony Biosciences LLC13$252
Vanda Pharmaceuticals Inc.15$249
Arbor Pharmaceuticals, Inc.19$245
Jazz Pharmaceuticals Inc.13$231
Sunovion Pharmaceuticals Inc.14$210
Octapharma USA, Inc.2$185
TG Therapeutics, Inc.7$180
Abbott8$178
Argenx US, Inc.8$172
Acorda Therapeutics, Inc9$168
Biohaven Pharmaceuticals, Inc.17$153
Idorsia Pharmaceuticals US Inc7$146
Sumitomo Pharma America, Inc.8$137
Acadia Pharmaceuticals Inc7$135
Azurity Pharmaceuticals, Inc.7$133
Biohaven Pharmaceutical Holding Company Ltd.13$130
Shire North American Group Inc9$127
Genentech USA, Inc.12$124
Avion Pharmaceuticals6$117
Grifols USA, LLC6$116
Impel Pharmaceuticals Inc.5$99
Hospira, Inc.3$82
Bausch Health US, LLC5$79
Otsuka Pharmaceutical Development & Commercialization, Inc.3$67
Tonix Medicines, Inc.3$65
Livanova USA, Inc.3$64
Novartis3$60
E.r. Squibb & Sons, L.L.C.3$56
Sanofi-aventis U.S. LLC3$54
Kyowa Kirin, Inc.2$54
Vertical Pharmaceuticals, LLC3$50

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,515 in reported general payments places this provider in the 80th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$41,078
Medicare patients
192
Services billed
289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BetaseronInterferon Beta-1b14$208,195
CopaxoneGlatiramer Acetate13$76,205
BriviactBrivaracetam12$14,207
DilantinPhenytoin Sodium Extended11$5,910
Oxcarbazepine43$3,421
Gabapentin73$1,853
Levetiracetam47$1,775
Carbamazepine30$1,522
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine19$1,148
Naratriptan Hcl15$1,030
Lacosamide22$1,016
Pyridostigmine Bromide13$987
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen51$899
Propranolol Hcl ErPropranolol Hcl15$745
Donepezil Hcl48$661

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$1,175$76,20513 claims
UCB, Inc.Briviact$2,290$14,20712 claims
PfizerDilantin$929$5,91011 claims
Upsher-smith Laboratories LLCTopiramate$316$31923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 790 neurology providers in Illinois.

Other neurology in Northbrook

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →